C.?The Association for the Accreditation of Human Research Protection Programs Inc. today announced that it has awarded accreditation to four additional organizations, including one more in Korea.
The Association for the Accreditation of Human Research Protection Programs Inc
. today announced that it has awarded accreditation to four additional organizations, including one more in Korea. The newly accredited organizations are:
The accreditations are the latest example of AAHRPP’s continued growth throughout the research enterprise. They also reflect AAHRPP’s steady progress in achieving the goal of one standard worldwide for protecting research participants and advancing high-quality research.
“These accreditations underscore that AAHRPP’s standards apply equally well to organizations across the research spectrum,” said Marjorie A. Speers, Ph.D., AAHRPP president and CEO. “AAHRPP accreditation is widely regarded as the mark of a quality human research protection program worldwide.”
AAHRPP accreditation is available to U.S. and international organizations that conduct biomedical, behavioral or social sciences research involving human participants. To date, AAHRPP has accredited organizations in 46 states, Canada, China, India, Korea, Mexico, Singapore and Taiwan.
Since its founding in 2001, AAHRPP has been instrumental in persuading research organizations to focus on quality improvement and routinely assess their performance. As a result, today’s AAHRPP-accredited HRPPs can point to measurable improvements in advancing research, protecting participants and building public trust.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.